Reportstack

Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022

 

Naperville, IL -- (ReleaseWire) -- 04/30/2014 -- Reportstack, provider of premium market research reports announces the addition of Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022 market report to its offering
Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022

Summary

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Takeda Pharmaceuticals developed Entyvio for the treatment of moderate to severe CD and UC. Takedas subsidiary, Millennium Pharmaceuticals, sponsored the Entyvio clinical trials, GEMINI I, GEMINI II, and GEMINI III, as well as the ongoing GEMINI LTS trial. Entyvio has been studied in 2,700 patients in nearly 40 countries, making it the largest Phase III clinical trial program ever conducted evaluating both CD and UC patients.

Scope

- Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
- Detailed information on Entyvio including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
- Sales forecast for Entyvio for the top eight countries from 2012 to 2022._x000D_
- Sales information covered for the US, France, Germany, Italy, Spain, the UK Japan and Canada.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis_x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
- Make more informed business decisions from insightful and in-depth analysis of Entyvio performance _x000D_
- Obtain sales forecast for Entyvio from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, the UK Japan and Canada)

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/153360/entyvio-ulcerative-colitis-forecast-and-market-analysis-to-2022.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###